PPA
GYRE icon

Parametric Portfolio Associates’s Gyre Therapeutics GYRE Stock Holding History

Parametric Portfolio Associates’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,803
Closed -$91K – 3629
2021
Q2 		$91K Sell
2,803
-3,028
-52% -$104K ﹤0.01% 3494
2021
Q1 		$220K Sell
5,831
-19
-0.3% -$868 ﹤0.01% 3840
2020
Q4 		$277K Buy
5,850
+2,443
+72% +$106K ﹤0.01% 3633
2020
Q3 		$110K Buy
+3,407
New +$133K ﹤0.01% 3778
2015
Q2 		– Sell
-50
Closed -$116K – 3978
2015
Q1 		$116K Hold
50
– – ﹤0.01% 3844
2014
Q4 		$103K Sell
50
-1
-2% -$1.93K ﹤0.01% 3897
2014
Q3 		$102K Buy
+51
New +$126K ﹤0.01% 3721
2014
Q2 		– Sell
-61
Closed -$227K – 3759
2014
Q1 		$227K Hold
61
– – ﹤0.01% 3578
2013
Q4 		$199K Sell
61
-2
-3% -$7.88K ﹤0.01% 3626
2013
Q3 		$262K Sell
63
-12
-16% -$48.3K ﹤0.01% 3466
2013
Q2 		$253K Buy
+75
New +$285K ﹤0.01% 3359

Other funds holding GYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Parametric Portfolio Associates's GYRE Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Gyre Therapeutics (GYRE) in Q3 2021, closing a stake of 2,803 shares — an estimated $91K sold.

Parametric Portfolio Associates first reported a position in GYRE in Q2 2013 and held it in 11 quarters. The position peaked at $277K in Q4 2020. 65 funds tracked by Wall St. Rank hold GYRE as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Gyre Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 2,803 Gyre Therapeutics shares in Q3 2021, an estimated $91K.
  • Parametric Portfolio Associates first reported a position in Gyre Therapeutics in Q2 2013 and held it in 11 quarters.
  • Parametric Portfolio Associates's Gyre Therapeutics position peaked at $277K in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.